Amgen Ltd, Uxbridge, UK.
Amgen GmbH, Vienna, Austria.
Biomark Med. 2017 Sep;11(9):751-760. doi: 10.2217/bmm-2016-0358. Epub 2017 Jul 27.
A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources.
MATERIALS & METHODS: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses.
The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources.
The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.
转移性结直肠癌的抗 EGFR 治疗通常需要明确野生型 RAS 肿瘤状态。本非干预性、观察性研究项目从实际来源估算 RAS 突变流行率。
从三个地区的 12 个来源中收集了 RAS 突变的综合数据。分别对每个来源进行分析，然后通过荟萃分析得出汇总的流行率估计值。
对 4431 个检测 RAS 突变状态的肿瘤样本进行的汇总 RAS 突变流行率估计为 43.6%（95%CI：38.8-48.5%）；来源之间的范围为 33.7%（95%CI：28.4-39.3%）至 54.1%（95%CI：51.7-56.5%）。
RAS 突变流行率估计值在来源之间存在差异。造成这种情况的原因尚不清楚，这突出表明需要进一步研究。
